Cell‐type Selective Phototoxicity Achieved with Chlorophyll‐a Derived Photosensitizers in a Co‐culture System of Primary Human Tumor and Normal Lung Cells
暂无分享,去创建一个
Barbara W. Henderson | Ravindra K. Pandey | Heinz Baumann | Erin Tracy | B. Henderson | R. Pandey | H. Baumann | Mary J. Bowman | E. Tracy | M. Bowman
[1] F. Guillemin,et al. Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. , 2006, Anti-cancer agents in medicinal chemistry.
[2] David Kessel,et al. Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.
[3] Hailong Wu,et al. Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.
[4] A. Kozubík,et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells , 2009, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[5] R. Pandey,et al. Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. , 2010, Molecular pharmaceutics.
[6] S. Bates,et al. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.
[7] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] W. Gallagher,et al. Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy , 2009, Photochemistry and photobiology.
[9] S. Nakahara,et al. Biological modulation by lectins and their ligands in tumor progression and metastasis. , 2008, Anti-cancer agents in medicinal chemistry.
[10] Micheline Piquette-Miller,et al. Regulation of drug transporters during infection and inflammation. , 2007, Molecular interventions.
[11] F. Guillemin,et al. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies. , 2008, Journal of medicinal chemistry.
[12] A. Yoshimura,et al. Increased expression of the LGALS3 (Galectin 3) gene in human non–small‐cell lung cancer , 2003, Genes, chromosomes & cancer.
[13] Konstantinos N. Halkiotis,et al. In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. , 1999, Mutagenesis.
[14] M. Calin,et al. Photodynamic therapy in oncology , 2006 .
[15] H. Pass,et al. Sensitivity of different human lung cancer histologies to photodynamic therapy. , 1990, Cancer research.
[16] Heinz Baumann,et al. Cross-Linking of Signal Transducer and Activator of Transcription 3—A Molecular Marker for the Photodynamic Reaction in Cells and Tumors , 2007, Clinical Cancer Research.
[17] C. Decaestecker,et al. Galectin‐3 Upregulation During Tumor Progression in Head and Neck Cancer , 2008, The Laryngoscope.
[18] Hideki Mori,et al. Neural stem/progenitor cells damaged by reactive oxygen species evolved in photosensitizing reaction , 2011, Neuroscience Letters.
[19] Heinz Baumann,et al. Photodynamic Therapy Causes Cross-linking of Signal Transducer and Activator of Transcription Proteins and Attenuation of Interleukin-6 Cytokine Responsiveness in Epithelial Cells , 2004, Cancer Research.
[20] R. Boyle,et al. Structure and Biodistribution Relationships of Photodynamic Sensitizers * , 1996, Photochemistry and photobiology.
[21] M. E. Kenney,et al. Structural Factors and Mechanisms Underlying the Improved Photodynamic Cell Killing with Silicon Phthalocyanine Photosensitizers Directed to Lysosomes Versus Mitochondria , 2009, Photochemistry and photobiology.
[22] Patrizia Agostinis,et al. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. , 2007, Biochimica et biophysica acta.
[23] Chao Liu,et al. In vitro cellular uptake and dimerization of signal transducer and activator of transcription-3 (STAT3) identify the photosensitizing and imaging-potential of isomeric photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a. , 2011, Journal of medicinal chemistry.
[24] T. Ishikawa,et al. Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.
[25] A. Johansson,et al. Tumor Selectivity at Short Times Following Systemic Administration of a Liposomal Temoporfin Formulation in a Murine Tumor Model , 2007, Photochemistry and photobiology.
[26] J. Frasor,et al. Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFκB Cooperativity at Adjacent Response Elements*♦ , 2010, The Journal of Biological Chemistry.
[27] Ekat Kritikou. Stem cells: Introducing the next generation , 2007, Nature Reviews Molecular Cell Biology.
[28] H. Zankl,et al. In vitro evaluation of the cytotoxic and mutagenic potential of the 5-aminolevulinic acid hexylester-mediated photodynamic therapy. , 2004, Mutation research.
[29] P. Acedo,et al. Mitotic catastrophe induced in HeLa cells by photodynamic treatment with Zn(II)-phthalocyanine. , 2008, International journal of oncology.
[30] G. Murphy. The ADAMs: signalling scissors in the tumour microenvironment , 2008, Nature Reviews Cancer.
[31] S. Rose-John,et al. Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells* , 2007, Journal of Biological Chemistry.
[32] Daniel B. Shin,et al. Photofrin Uptake in the Tumor and Normal Tissues of Patients Receiving Intraperitoneal Photodynamic Therapy , 2006, Clinical Cancer Research.
[33] G. Kéri,et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.
[34] J. Schuetz,et al. Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.
[35] M. McNiven,et al. Dynamin 2 mediates fluid-phase micropinocytosis in epithelial cells , 2007, Journal of Cell Science.
[36] Satyajit Mayor,et al. Pathways of clathrin-independent endocytosis , 2007, Nature Reviews Molecular Cell Biology.
[37] J. Behravan,et al. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX , 2009, Inflammation Research.
[38] Janet Morgan,et al. The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2 , 2007, Clinical Cancer Research.
[39] Frédéric Blanchard,et al. Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines , 2005, BMC Cancer.
[40] B. Henderson,et al. Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. , 2009, Journal of medicinal chemistry.
[41] K. Sakakura,et al. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. , 2009, Oral oncology.
[42] T. Ishikawa,et al. Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis , 2010, Advances in pharmacological sciences.
[43] F. S. Pardo,et al. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. , 2008, Archives of otolaryngology--head & neck surgery.
[44] Nancy L Oleinick,et al. The role of apoptosis in response to photodynamic therapy: what, where, why, and how , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[45] T. Kiesslich,et al. Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. , 2006, Current medicinal chemistry.
[46] J. Usuda,et al. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. , 2010, Lung cancer.
[47] Robert W. Robey,et al. Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells , 2009, Cancer Chemotherapy and Pharmacology.
[48] Michael Dean,et al. The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. , 2006, Research in veterinary science.
[49] Mukund Seshadri,et al. Light Delivery over Extended Time Periods Enhances the Effectiveness of Photodynamic Therapy , 2008, Clinical Cancer Research.